Prosecution Insights
Last updated: May 04, 2026
Application No. 18/468,396

NEW THIADIAZOLOPYRIMIDONE DERIVATIVES

Non-Final OA §102
Filed
Sep 15, 2023
Priority
Mar 17, 2021 — EU 21163263.3 +1 more
Examiner
LEESER, ERICH A
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche, Inc.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
774 granted / 949 resolved
+21.6% vs TC avg
Moderate +14% lift
Without
With
+13.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
17 currently pending
Career history
966
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
13.0%
-27.0% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
38.3%
-1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 949 resolved cases

Office Action

§102
DETAILED ACTION This action is in response to Applicant’s submission dated March 12, 2026, in which Applicant elected the invention of Group I as well as the species of Example 1, both without traverse. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The references in the IDS dated April 26, 2024 are made of record. Election/Restriction Claims 37-40 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a non-elected Groups II and IIII, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on March 12, 2026. The requirement is still deemed proper and is therefore made FINAL. Claims 23-36 and 41 are examined. A complete reply to the final rejection must include cancellation of non-elected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 23-25, 27-30, 36, and 41 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Reynolds, et al, US 2024/0279239 based on its priority date of April 8, 2020 from application No. 63/007,327. Reynolds, et al. teaches compounds and methods for modulating splicing, which include instant compounds. Specifically, the compound with the structure: PNG media_image1.png 196 460 media_image1.png Greyscale of the reference anticipates the aforementioned claims where R1 is 6-member heterocycloalkyl substituted with two R4 that are cyclopropyl and C4 alkoxy-carbonyl; R2 is halogen (fluoro), R3 is C1 alkyl, and A1 is CH. The references compounds exhibit the same activity as the compounds of the instant claims. Claim Objections Claims 26 and 31-35 are objected to as being dependent upon rejected independent claim 23, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICH A LEESER/Primary Examiner, Art Unit 1622 United States Patent and Trademark Office Tel. No.: (571) 272-9932
Read full office action

Prosecution Timeline

Sep 15, 2023
Application Filed
Apr 18, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12612390
MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
3y 0m to grant Granted Apr 28, 2026
Patent 12590082
FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF
3y 0m to grant Granted Mar 31, 2026
Patent 12589099
ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY
2y 6m to grant Granted Mar 31, 2026
Patent 12590106
SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
11m to grant Granted Mar 31, 2026
Patent 12570622
THERAPEUTIC COMPOUNDS
3y 3m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
95%
With Interview (+13.5%)
2y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 949 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month